Axol Bioscience Gets $3-Million Capital Investment
The private equity funding will enable the startup biotech firm to expand product development as well as sales and marketing capabilities.
On August 15, 2017, Calculus Capital (London), a private equity firm, announced that it invested £2.5 million ($3.2 million) in Axol Bioscience (Cambridge, UK), a provider of stem cells produced from reprogrammed human blood and tissue cells.
Axol, founded in 2012, supplies human cells, especially live human neurons, created by stem cell technology to pharma companies and research institutions. The cells are used for medical research, disease modeling, and drug development. The company generates stem cells from blood and tissue cells extracted from healthy and diseased patients. These cells can self-renew and may be used to become any tissue in the human body. Each cell line that Axol produces is identical to the previous production batch, ensuring quality and consistency for research and drug development projects.
“Axol Bioscience is doing very important work; its products and services-stem cells and the culture systems required to maintain them-are essential to gene-based medical research. Our investment will enable Axol to grow and develop more product lines that are able to make a real and effective contribution to medical research efforts to combat killer diseases,” said Alexandra Lindsay, investment director at Calculus Capital, in a company press release.
“The market for our products is growing rapidly, all around the world, and the funding from Calculus will help us to make the most of that opportunity through new product development and increasing our sales and marketing capabilities,” said Axol CEO Yichen Shi, PhD, in the press release.
Source: Calculus Capital
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
